soft tissue sarcoma

Related by string. soft tissue sarcomas * softer . Softer . Soft . SOFT . softs : Soft ware . carbonated soft drinks . soft liner . soft drinks . carbonated soft drink / tissues . Tissues . Tissue . TISSUE : remove scar tissue . tissue samples . scar tissue . Tissue samples . Scar tissue / sarcomas . Sarcoma . Sarcomas : Ewing sarcoma . Ewing Sarcoma . Ewing sarcoma rare . Soft Tissue Sarcoma . Soft tissue sarcomas * *

Related by context. All words. (Click for frequent words.) 66 soft tissue sarcomas 65 metastatic colorectal cancer 64 metastatic melanoma 63 NSCLC 63 sarcoma 62 unresectable 61 mCRC 61 metastatic breast cancer 60 renal cell carcinoma 60 metastatic renal cell carcinoma 60 metastatic GIST 60 hormone refractory prostate cancer 60 pancreatic adenocarcinoma 59 malignant pleural mesothelioma 59 Acute Myelogenous Leukemia AML 59 HER2 positive metastatic breast 59 IV NSCLC 59 recurrent NSCLC 59 B CLL 59 hepatocellular cancer 59 Hepatocellular Carcinoma HCC 59 advanced NSCLC 58 osteosarcoma 58 Amrubicin 58 IV metastatic melanoma 58 lymphoma CTCL 58 multiple myeloma 58 platinum refractory 58 acute myelogenous leukemia AML 58 cell lung cancer 58 metastatic pancreatic cancer 58 IV melanoma 57 metastatic 57 gastrointestinal stromal tumor 57 metastatic RCC 57 mRCC 57 sarcomas 57 hepatocellular carcinoma HCC 57 astrocytoma 57 recurrent glioblastoma multiforme 57 HER2 positive 57 basal cell carcinoma BCC 57 metastatic CRC 57 relapsed refractory multiple myeloma 57 myelodysplastic syndrome MDS 57 stage IIIB 57 brain metastases 57 HNSCC 57 non squamous 57 non metastatic osteosarcoma 56 fallopian tube carcinoma 56 metastatic renal cell 56 gastric cancer 56 gastrointestinal stromal tumor GIST 56 advanced unresectable 56 follicular lymphoma 56 imatinib resistant 56 refractory multiple myeloma 56 metastatic colon cancer 56 hepatocellular carcinoma 56 cutaneous T cell 56 tumors GIST 55 acute myeloid leukemia AML 55 tumor recurrence 55 resectable 55 glioblastoma multiforme GBM 55 solid tumors 55 myelodysplastic syndromes MDS 55 prostate cancer CRPC 55 metastatic colorectal 55 carcinoma 55 non squamous NSCLC 55 metastatic carcinoma 55 HER2 positive breast cancer 55 glufosfamide 55 OPAXIO 55 pancreatic NET 55 systemic ALCL 55 leiomyosarcoma 55 neuroendocrine tumors 55 TORISEL 55 melanoma 55 ongoing Phase 1b 55 aHUS 55 chronic lymphocytic leukemia 55 pheochromocytoma 55 metastatic NSCLC 55 metastatic cancer 55 thymoma 54 medically inoperable 54 relapsed refractory 54 leukemia CLL 54 multiple myeloma MM 54 mCRC patients 54 acute leukemias 54 metastatic HRPC 54 lupus nephritis 54 Li Fraumeni Syndrome 54 Glioblastoma Multiforme 54 HRPC 54 squamous cell carcinoma 54 metastatic disease 54 metastatic prostate cancer 54 indolent NHL 54 cell lymphoma CTCL 54 papillary renal cell carcinoma 54 hypoparathyroidism 54 carboplatin paclitaxel 54 metastatic malignant melanoma 54 hypophosphatasia 54 cutaneous melanoma 54 grade glioma 54 refractory Hodgkin lymphoma 54 carcinoid tumors 54 nasopharyngeal cancer 54 EGFR mutation positive 54 radiation sensitizer 54 RCW breast cancer 54 gastric cancers 54 chronic lymphocytic leukemia CLL 54 palifosfamide 54 axitinib 54 DIPG 54 nimotuzumab 53 stage IIIA 53 metastatic pancreatic 53 systemic lupus erythematosus 53 metastatic gastric 53 gastrointestinal stromal tumors 53 relapsed SCLC 53 leukemia AML 53 recurrent glioblastoma 53 heavily pretreated 53 refractory AML 53 phase IIb clinical 53 Vectibix 53 severe oral mucositis 53 Acute Myeloid Leukemia AML 53 vandetanib 53 metastatic lung cancer 53 prostate cancer mCRPC 53 squamous cell carcinoma SCC 53 follicular lymphoma FL 53 diffuse intrinsic pontine glioma 53 relapsed ovarian cancer 53 metastatic CRPC 53 resistant ovarian cancer 53 vinorelbine 53 unresectable stage 53 liver metastases 53 colorectal cancer 53 advanced hepatocellular carcinoma 53 lymphocytic leukemia 53 KRAS mutations occur 53 recurrent glioma 53 bladder cancers 53 pancreatic carcinoma 53 bevacizumab Avastin ® 53 Fludara ® 53 distant metastasis 53 locoregional 53 acute promyelocytic leukemia APL 53 squamous cell cancer 53 malignant melanoma 53 nonsmall cell lung cancer 53 Ewing sarcoma 53 MALT lymphoma 53 differentiated thyroid 53 grade cervical intraepithelial 53 hematologic malignancies 53 unresectable locally advanced 53 medullary thyroid cancer 53 AA amyloidosis 53 prostate carcinoma 53 trastuzumab DM1 T DM1 53 acute myeloid 53 Aplidin 53 ADVEXIN therapy 53 idiopathic pulmonary fibrosis IPF 53 acute ischemic stroke 53 stage IIIB IV 53 juvenile idiopathic arthritis 53 histologies 52 metastatic liver 52 metastatic bladder 52 Proxinium TM 52 ependymoma 52 cetuximab 52 refractory metastatic colorectal cancer 52 Yondelis ® 52 grade gliomas 52 relapsing multiple sclerosis 52 randomized Phase IIb 52 recurrent ovarian cancer 52 nasopharyngeal carcinoma 52 biliary cancer 52 transitional cell carcinoma 52 sorafenib Nexavar ® 52 dasatinib 52 hematological cancers 52 relapsing remitting multiple sclerosis 52 invasive bladder 52 KRAS wild 52 cutaneous squamous cell carcinoma 52 Wilms tumor 52 vemurafenib 52 cholangiocarcinoma 52 oral ridaforolimus 52 recurrent metastatic 52 refractory prostate cancer 52 myelodysplastic syndromes 52 Soft Tissue Sarcoma 52 small lymphocytic lymphoma 52 GIST 52 SCCHN 52 elacytarabine 52 superficial bladder cancer 52 invasive candidiasis 52 untreated metastatic melanoma 52 malignant lymphoma 52 synovial sarcoma 52 IMGN# 52 cancer mCRC 52 minimally symptomatic 52 MabCampath 52 CLL SLL 52 chlorambucil 52 myelofibrosis 52 leukemia ALL 52 IV malignant melanoma 52 non metastatic resectable 52 Acute Myeloid Leukaemia AML 52 malignancies 52 rhabdomyosarcoma 52 assessing T DM1 52 Acute Myeloid Leukemia 52 BR.# 52 Multiple Myeloma MM 52 colorectal liver metastases 52 cell carcinoma 52 lymphoma 52 Burkitt lymphoma 52 Waldenstrom macroglobulinemia 52 advanced metastatic renal 52 stage IIIb IV 52 Advexin 52 pancreatic neuroendocrine tumors 52 chronic myelogenous leukemia CML 52 AP# [003] 52 pertuzumab 52 CABP 52 HCV infection 52 acute myeloid leukemia 52 depsipeptide 52 trabectedin 51 epithelial ovarian 51 breast carcinoma 51 lymph node involvement 51 relapsing remitting MS 51 temsirolimus 51 hypercalcemia 51 cervical dysplasia 51 ZEVALIN 51 locoregional disease 51 malignant neoplasms 51 Gorlin syndrome 51 castration resistant prostate cancer 51 EGFR expressing 51 sorafenib 51 neoadjuvant treatment 51 peritoneal carcinomatosis 51 metastatic renal 51 metastatic castrate resistant 51 chronic myeloid leukemia CML 51 dacarbazine 51 ganetespib 51 CMV disease 51 completely resected 51 follicular NHL 51 T DM1 51 squamous 51 adecatumumab 51 atypical Hemolytic Uremic Syndrome 51 GISTs 51 histologically confirmed 51 Chronic lymphocytic leukemia 51 docetaxel chemotherapy 51 diagnosed multiple myeloma 51 Torisel 51 carcinoma HCC 51 urothelial carcinoma 51 gemcitabine chemotherapy 51 neoadjuvant therapy 51 distant metastases 51 recurrent malignant glioma 51 BRIM3 51 prognostic variables 51 myeloma 51 CTCL 51 actinic keratosis 51 Ceflatonin 51 cytotoxic chemotherapy 51 prostate cancer HRPC 51 pain palliation 51 bone metastases 51 Imprime PGG 51 neratinib 51 superficial basal cell carcinoma 51 refractory chronic lymphocytic 51 squamous cell 51 metastatic breast 51 tamibarotene 51 recurrent glioblastoma multiforme GBM 51 neoplasm 51 tumor lysis syndrome 51 Targretin 51 HBeAg negative 51 indolent follicular non 51 cisplatin chemotherapy 51 acute myelogenous leukemia 51 metastatic cancers 51 relapsed multiple myeloma 51 Hodgkin lymphoma 51 lobular carcinoma 51 chemoradiotherapy 51 severe sepsis 51 paraganglioma 51 embryonal rhabdomyosarcoma 51 liposomal doxorubicin 51 gemcitabine 51 gastrointestinal cancers 51 liposarcoma 51 seminoma 51 docetaxel Taxotere R 51 pleural mesothelioma 51 Multiple Myeloma 51 carcinoid cancer 51 gastrointestinal stromal tumors GIST 51 anaplastic astrocytoma 51 randomized Phase III 51 peritoneal cancer 51 prostate adenocarcinoma 51 sunitinib 51 chronic myeloid 51 Onrigin 51 acute myelogenous 51 Genasense ® 51 recurrent squamous cell carcinoma 51 TELCYTA 51 adjuvant radiation 51 premalignant 51 cell carcinoma RCC 51 Metastatic Colorectal Cancer 51 cutaneous T 51 Fludara 51 plus gemcitabine 51 docetaxel 51 bone metastasis 51 evaluating tivozanib 50 bevacizumab Avastin 50 tanespimycin 50 colorectal cancers 50 PROSTVAC ® 50 Cloretazine 50 gemcitabine carboplatin 50 dasatinib Sprycel ® 50 metastatic relapsed 50 remission induction 50 lung metastases 50 situ CIS 50 evaluating T DM1 50 neoplasia 50 leukemia APL 50 azacitidine 50 ponatinib 50 EGFR HER2 50 Wegener granulomatosis 50 SJIA 50 evaluating picoplatin 50 Metastatic breast cancer 50 ZACTIMA 50 TRISENOX 50 IL# PE#QQR 50 adrenocortical carcinoma 50 carcinomas 50 Nexavar sorafenib 50 Virulizin ® 50 eosinophilic asthma 50 pazopanib 50 adenocarcinoma 50 CYT# potent vascular disrupting 50 Adjuvant chemotherapy 50 aflibercept 50 mycosis fungoides 50 myeloproliferative disorders 50 erlotinib Tarceva ® 50 relapsed Acute Myeloid 50 metastatic castration resistant 50 clofarabine 50 metastatic HER2 positive 50 bevacizumab 50 infusional 5-FU/LV 50 Osteosarcoma 50 epithelial tumors 50 docetaxel Taxotere ® 50 nonmetastatic 50 ELACYT 50 Hodgkin lymphoma HL 50 Surgical resection 50 randomized Phase 50 acute coronary syndromes ACS 50 evaluable patients 50 smoldering myeloma 50 neoplasias 50 neoadjuvant chemotherapy 50 familial amyloidotic polyneuropathy FAP 50 breast carcinomas 50 metastatic hormone refractory 50 cetuximab Erbitux ® 50 metastatic malignant 50 geographic atrophy 50 refractory acute myeloid 50 squamous histology 50 non resectable 50 castrate resistant prostate cancer 50 PNET 50 TTF Therapy 50 ThermoDox ® 50 5 fluorouracil leucovorin 50 CLL 50 colorectal liver 50 recurrent GBM 50 systemic lupus erythematosus SLE 50 smoldering multiple myeloma 50 chronic HBV infection 50 HER2 overexpression 50 Rhabdomyosarcoma 50 Acute Myelogenous Leukemia 50 paclitaxel carboplatin 50 ThermoDox R 50 gefitinib 50 sunitinib malate 50 palliative radiotherapy 50 Hodgkin Lymphoma 50 angiosarcoma 50 adjuvant therapy 50 NMIBC 50 relapsed AML 50 glioblastoma 50 perifosine 50 refractory gout 50 systemic anaplastic large 50 cSSSI 50 imetelstat 50 refractory chronic myeloid 50 biliary strictures 50 alvespimycin 50 Glioblastoma Multiforme GBM 50 squamous cell lung cancer 50 Alessandro Riva 50 Crohn disease 50 Toxicities 50 metastatic ovarian cancer 50 clinically localized prostate 50 NSABP 50 registrational trial 50 Azedra 50 ADVEXIN 50 LHRH receptor positive 50 relapsed MM 50 Cell Lymphoma 50 lymphoid malignancies 50 Cholangiocarcinoma 49 systemic scleroderma 49 pancreatic prostate 49 juvenile myelomonocytic leukemia 49 neoadjuvant 49 imatinib 49 HER2 positive cancers 49 autoantibody positive 49 hypereosinophilic syndrome 49 kidney urologic 49 myelofibrosis MF 49 histological subtype 49 ToGA 49 BRIM2 49 adenocarcinomas 49 dysplasia 49 neuroendocrine cancers 49 sorafenib tablets 49 contralateral breast 49 chronic ITP 49 biliary tract cancer 49 Junovan 49 hematologic disorders 49 Glioblastoma multiforme 49 renal tumors 49 EGFR expressing mCRC 49 unresectable liver cancer 49 proliferative diabetic retinopathy 49 diabetic nephropathy 49 chemotherapy regimens 49 peripheral arterial disease 49 Dacogen injection 49 ovarian carcinoma 49 malignancy 49 Tavocept 49 temsirolimus Torisel ® 49 Vandetanib 49 recurrent colorectal cancer 49 refractory gastrointestinal stromal 49 ACTEMRA TM 49 carcinoid 49 advanced epithelial ovarian 49 antibody MAb 49 Tarceva TM 49 ACTEMRA 49 Radiation Therapy Oncology 49 Velcade bortezomib 49 subependymal giant cell 49 Acute myeloid leukemia 49 dacarbazine chemotherapy 49 malignant growths 49 BRAF inhibitor 49 acute GvHD 49 HGS ETR1 49 rheumatoid arthritis psoriatic arthritis 49 Nimotuzumab 49 taxane therapy 49 Cloretazine ® 49 FOLOTYN ® 49 FOLOTYN 49 glioblastoma brain tumor 49 microwave hyperthermia 49 essential thrombocythemia 49 malignant fibrous histiocytoma 49 HER2 negative 49 OncoVEX GM CSF 49 Cutaneous T 49 ELOXATIN 49 refractory APL 49 lymphoblastic lymphoma 49 Vicinium TM 49 invasive aspergillosis 49 heterozygous FH 49 Brentuximab Vedotin SGN 49 leukemias lymphomas 49 amifampridine phosphate 49 KRAS mutant 49 FOLFIRI 49 operable breast cancer 49 AA Amyloidosis 49 TTR amyloidosis 49 Nexavar ® 49 TYZEKA 49 non Hodgkin lymphoma 49 diffuse gastric 49 aflibercept VEGF Trap 49 satraplatin Phase 49 sodium thiosulfate STS 49 BCIRG 49 opioid induced constipation OIC 49 PANVAC VF 49 imatinib Gleevec ® 49 cervical carcinoma 49 refractory 49 CEQ# 49 refractory indolent non 49 Motesanib 49 lymphomas 49 primitive neuroectodermal tumor 49 urothelial cancer 49 keloid scarring 49 Acute Lymphoblastic Leukemia 49 Chronic Myelogenous Leukemia CML 49 papillary thyroid cancer 49 pralatrexate 49 epithelial cancers 49 INCB# [003] 49 nodal metastasis 49 plaque psoriasis 49 Phase 2b clinical 49 papillary 49 Advanced Renal Cell 49 ixabepilone 49 sorafenib Nexavar 49 Malignant Melanoma 49 Myelodysplastic Syndrome 49 metastatic kidney 49 trastuzumab emtansine T DM1 49 essential thrombocythemia ET 49 Follicular Lymphoma 49 CIN2 + 49 Hodgkin lymphoma NHL 49 TheraCIM 49 pemetrexed 49 biologic therapy 49 GvHD 49 myeloproliferative disorder 49 grade dysplasia 49 Yondelis 49 anterior uveitis 49 refractory PTCL 49 MAGE A3 ASCI 49 advanced nonsquamous NSCLC 49 prostate cancers 49 zalutumumab 49 trastuzumab 49 FOLFOX 49 Cloretazine R VNP#M 49 Wilms tumors 49 dacarbazine DTIC 49 Burkitt Lymphoma 49 skeletal metastases 49 ThermoDox 49 heavily pretreated patients 49 Chronic Lymphocytic Leukemia CLL 49 NYHA Class II 49 Zevalin consolidation 49 severe plaque psoriasis 49 neuroblastoma 49 tesetaxel 49 hematological malignancies 49 localized renal 49 allogeneic hematopoietic stem cell 49 tivozanib 49 patients evaluable 49 prostate cancer PCa 49 cisplatin resistant 49 vismodegib 49 DLBCL 49 invasive fungal infections 49 PCNSL 49 Nexavar 49 symptomatic BPH 49 NovoTTF 49 TheraSphere 49 obatoclax 49 RTOG 49 fibromyalgia syndrome 49 INCB# [001] 49 capecitabine Xeloda R 49 Chronic Myeloid Leukemia 49 nodal metastases 49 Metastatic Melanoma 49 non hodgkin lymphoma 49 PROVENGE 49 tumoral 49 relapsed leukemia 49 monotherapy 49 metastatic basal cell 48 osteogenic sarcoma 48 juvenile idiopathic arthritis JIA 48 pulmonary metastasis 48 EGFR mutations 48 Zolinza 48 Cell Lung Cancer 48 Basal cell 48 nilotinib Tasigna ® 48 pT2 48 allogeneic bone marrow 48 Duchenne Muscular Dystrophy DMD 48 ankylosing spondylitis AS 48 bendamustine 48 lymphoma subtypes 48 CINTREDEKIN BESUDOTOX 48 pulmonary arterial hypertension PAH 48 romiplostim 48 Glioblastoma 48 IMA# 48 HUMIRA 48 afatinib 48 relapsed GBM 48 precursor lesions 48 panitumumab 48 irinotecan chemotherapy 48 lung carcinomas 48 chronic periodontitis 48 bortezomib 48 osteosarcoma rare 48 phase IIb study 48 alveolar rhabdomyosarcoma 48 metastatic uveal melanoma 48 hormone refractory metastatic prostate 48 Acute Leukemia 48 antitumor activity 48 nilotinib 48 Carcinoma 48 refractory CLL 48 adenoid cystic carcinoma 48 hepatoblastoma 48 FluCAM arm 48 esophageal carcinoma 48 CHOP chemotherapy 48 registrational 48 TNF antagonist 48 oligodendrogliomas 48 thymic carcinoma 48 neuronal ceroid lipofuscinosis NCL 48 anti EGFR antibody 48 HGS# 48 renal carcinoma 48 Allovectin 7 48 radiofrequency ablation RFA 48 Wilms Tumor 48 histological subtypes 48 gastric carcinoma 48 cetuximab Erbitux 48 Hepatocellular Carcinoma 48 Phase #/#a trial 48 pT3 48 EFAPROXYN 48 PI3K/Akt pathway inhibitor 48 de novo AML 48 esophageal cancers 48 T1DM 48 paroxysmal nocturnal hemoglobinuria PNH 48 chronic plaque psoriasis 48 FOLFOX regimen 48 ovarian lung 48 chemoradiation 48 atypical hemolytic uremic syndrome 48 RoACTEMRA 48 Allovectin 7 ® 48 ALS Amyotrophic Lateral Sclerosis 48 parathyroid carcinoma 48 docetaxel prednisone 48 plus dexamethasone 48 mapatumumab 48 leukemia CML 48 TG MV 48 monoclonal antibody conjugated 48 T1a 48 malignant ascites 48 S. aureus infections 48 liver cancer 48 Ph + ALL 48 Renal Cell Carcinoma RCC 48 adverse cytogenetics 48 prostate cancer CaP 48 uveitis 48 cancers 48 gastroesophageal junction 48 osteosarcomas 48 satraplatin 48 standard chemotherapy regimens 48 Cloretazine R 48 pancreatic islet cell 48 xenograft models 48 Phase #b/#a clinical 48 malignant neoplasm 48 Phase Ib 48 HER2 + 48 acute lymphoblastic 48 HCV genotype 48 pediatric sarcoma 48 Ewing Sarcoma 48 hematologic toxicity 48 cystic fibrosis CF 48 activating EGFR mutations 48 EGFR TKI 48 cetuximab Erbitux R 48 relapsed acute lymphoblastic 48 myelofibrosis polycythemia vera 48 SIR Spheres 48 Tamibarotene 48 fluoropyrimidine 48 transplantation HSCT 48 hepatic metastases 48 cancer 48 cIAI 48 picoplatin 48 nonmelanoma skin cancers 48 axillary lymph node 48 adjuvant radiotherapy 48 Systemic Lupus Erythematosus SLE 48 MOZOBIL 48 pomalidomide 48 hepatocellular carcinomas 48 IIIB NSCLC 48 histologic subtype 48 RRMS 48 prostate cancer AIPC 48 AVONEX ® 48 anaplastic thyroid cancer 48 prostate carcinomas 48 SUTENT 48 Folfox 48 BRCA deficient 48 huC# DM4 48 immune thrombocytopenic purpura ITP 48 LUX Lung 48 relapsed ALL 48 Synovial sarcoma 48 calcineurin inhibitor 48 Alocrest 48 CYT# 48 VELCADE 48 metastatic squamous cell carcinoma 48 myeloproliferative diseases 48 UPLYSO 48 PEGylated interferon beta 1a 48 colorectal 48 anthracycline taxane 48 Annamycin 48 CYPHER Stent 48 ASA# 48 Myelofibrosis 48 investigational monoclonal antibody 48 prospectively defined 48 talactoferrin 48 pediatric malignancies 48 hematologic cancers 48 unresectable tumors 48 dirucotide 48 Peginterferon alfa 2b 48 Hematologic 48 YONDELIS 48 synovial cell 48 venous thromboembolic events 48 gastric adenocarcinoma 48 lung pancreatic 48 Papillary 48 Sezary syndrome 48 galiximab 48 oral Hycamtin 48 resistant hormone refractory 48 TACI Ig 48 curative resection 48 TEMODAL 48 erlotinib 48 humanised monoclonal antibody 48 gefitinib Iressa 48 KRAS mutation 48 lymph node metastases 48 refractory cutaneous T 48 gastrointestinal malignancies 48 palliation 48 common hematologic malignancy 48 commercialize deforolimus 48 refractory ovarian cancer 48 immunocompromised patients 48 rectal cancers 48 colorectal cancer CRC 48 Metastatic melanoma 48 Kit CD# positive 48 cutaneous malignancies 48 multicenter randomized controlled 48 phase IIa clinical 48 neovascular diseases 48 TNF blocker therapy 48 Severe Primary IGFD 48 hormone receptor positive 48 trastuzumab DM1 48 psoriasis 48 metastatic colorectal carcinoma 48 Gleevec imatinib 48 arthritis PsA 48 dose escalation Phase 48 Ewing sarcoma rare 48 Non Hodgkin 48 interstitial pneumonia 48 non Hodgkin Lymphoma 48 dasatinib Sprycel 48 Halaven 48 virus HCV infection 48 pivotal Phase III 48 chronic ITP patients 48 relapsing remitting 48 malignant pancreatic 48 papillary carcinoma 48 cardiac dysfunction 48 Actemra tocilizumab 48 myeloproliferative 47 histone deacetylase HDAC inhibitor 47 Doxil ® 47 Gastric cancer 47 localized prostate cancer 47 refractory acute promyelocytic 47 unresectable Stage III 47 pegylated liposomal doxorubicin 47 ALIMTA 47 panitumumab Vectibix 47 melphalan prednisone 47 Chronic Lymphocytic Leukemia 47 stage IIIb 47 phase IIb 47 refractory NSCLC 47 receptor tyrosine kinase inhibitor 47 endometrial hyperplasia 47 actinic keratoses 47 chemotherapy cisplatin 47 colorectal cancer liver metastases 47 MGUS 47 renal insufficiency 47 medulloblastoma 47 taxane refractory 47 orthotopic model 47 meningiomas 47 chronic granulomatous disease 47 primary immunodeficiency PI 47 clinical trial 47 Stage IIIb 47 squamous cell carcinomas 47 trastuzumab Herceptin R 47 Phase 1b clinical 47 VELCADE melphalan 47 medulloblastoma malignant brain tumor 47 forodesine 47 Myelodysplastic Syndrome MDS 47 FTY# 47 cisplatin 47 lung cancer NSCLC 47 amrubicin 47 Idiopathic pulmonary fibrosis 47 metastases 47 Nexavar tablets 47 Rituxan rituximab 47 precancerous cervical lesions 47 biochemical recurrence 47 placebo controlled clinical 47 lymphocytosis 47 nonsquamous histology 47 PDX pralatrexate 47 chronic kidney 47 Soft tissue sarcomas 47 EGFR inhibitors 47 posterior uveitis 47 squamous cell cancers 47 oral mucositis 47 TACE 47 anticancer compound 47 systemic mastocytosis 47 randomized Phase 2b 47 CRVO 47 Gleevec resistant 47 IRX 2 47 chronic myelogenous leukemia 47 PREZISTA r 47 invasive ductal carcinoma 47 malignant pheochromocytoma 47 thromboembolic events 47 Myelodysplasia 47 prospective multicenter 47 Herceptin trastuzumab 47 metastatic neuroendocrine tumors 47 Idiopathic Pulmonary Fibrosis 47 visceral metastases 47 hereditary angioedema HAE 47 fludarabine 47 lorvotuzumab mertansine 47 chronic HCV infection 47 invasive carcinoma 47 recurrent prostate cancer 47 factor receptor EGFR 47 EGFR targeting 47 hematological malignancy 47 ceroid lipofuscinosis NCL 47 Perifosine 47 HoFH 47 EOquin TM 47 Myelodysplastic Syndromes MDS 47 APPRAISE 47 Vidaza ® 47 recurrent refractory 47 posaconazole 47 complete remissions 47 atopic dermatitis AD 47 AEG# 47 chondrosarcoma 47 hematological diseases 47 histone deacetylase inhibitor 47 panobinostat 47 Ceplene/IL-2 47 myeloid leukemia 47 gemcitabine Gemzar ® 47 ALA PDT 47 Sudhir Agrawal D.Phil 47 Avastin bevacizumab 47 anti leukemic 47 hepatorenal syndrome 47 mildly symptomatic 47 Neovascular AMD 47 follicular non 47 liver metastasis 47 LHON 47 evaluable subjects 47 APOPTONE 47 Genasense 47 MYLOTARG 47 Atypical Hemolytic Uremic Syndrome 47 talabostat 47 carcinoma mCRC 47 Rectal cancer 47 mTOR inhibitor 47 epithelial ovarian cancer 47 Myelodysplastic Syndromes 47 chemoresistant 47 brain tumor glioblastoma multiforme

Back to home page